PALOMA2, a double-blind, phase III trial of palbociclib plus letrozole vs placebo plus letrozole as a first-line treatment of postmenopausal patients with ER+/HER2- advanced breast cancer was confirmatory and should be reported soon. Here, ESR1 is linked to breast carcinoma.